Baricinix 4 mg and 2 mg , powered by Baricitinib , is a breakthrough oral medication used to treat moderate to severe Therapy for rheumatoid arthritis and COVID-19 complications in certain hospitalized patients. As a Janus kinase (JAK) inhibitor, Baricinix targets specific enzymes that cause inflammation in autoimmune diseases like rheumatoid arthritis. It has recently been approved for managing severe…
Rematib 15mg, powered by Upadacitinib, is an innovative, targeted therapy designed to Rheumatoid arthritis treatments and other inflammatory conditions. As a Janus kinase (JAK) inhibitor, Rematib 15mg effectively reduces the overactive immune response that leads to inflammation, pain, and joint damage. This oral medication is a game-changer for patients who have not responded well to traditional Rheumatoid arthritis treatments, offering…
